- |||||||||| Votrient (pazopanib) / Novartis
Journal: Metabolic Response by 18F-FDG PET/CT in Metastatic Malignant Struma Ovarii Treated With Targeted Therapies. (Pubmed Central) - Nov 14, 2020 We report a metabolic response assessed by F-FDG PET/CT in a 71-year-old woman with radioiodine-refractory metastatic MSO treated by targeted therapies (first line with lenvatinib and second line with pazopanib). This case of exceptional response also highlights the usefulness of F-FDG PET/CT for therapeutic assessment of targeted drugs in such a rare clinical entity of malignant MSO.
- |||||||||| Preclinical, Journal: Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy. (Pubmed Central) - Nov 14, 2020
Lenvatinib, a multiple tyrosine kinase inhibitor including VEGFR and FGFR inhibition, showed marked antitumor activity against VEGFR2-Fc-expressing resistant tumors accompanied with a decrease in the area of tumor vessels and suppression of phospho-FGFR2 in tumors. Our findings reveal the key role that intercellular FGF2 signaling between pericytes and endothelial cells plays in maintaining the tumor vasculature in anti-VEGF therapy-resistant tumors.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, PD(L)-1 Biomarker, IO biomarker: NeoPele: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (clinicaltrials.gov) - Nov 13, 2020 P2, N=20, Recruiting, │ Objectives: Evaluate the efficacy and safety from the REFLECT trial that supports the use of LENVIMA as a first-line treatment option in patients with unresectable HCC (uHCC) Review patient case with uHCC to highlight potential treatment outcomes and adverse event management strategies associated with LENVIMA Not yet recruiting --> Recruiting
- |||||||||| lenvatinib / Generic mfg.
Biomarker, Clinical, Journal: Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports. (Pubmed Central) - Nov 3, 2020 This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Presentation 3 () - Oct 29, 2020 - Abstract #ESGO2020ESGO_120; N=135 --> 315 Brief overview of treatment approaches for MMRp EC patients Current Chemotherapy Future IO monotherapy (dostarlimab, pembrolizumab, avelumab) AI + CDKi (letrozole + palbociclib, NGOT-EN3/NSGO-PALEO study) VEGF + IO (lenvatinib + pembrolizumab, cabozantinib + nivolumab) Chemotherapy + IO (phase 3 trials in progress: pembrolizumab + chemotherapy, atezolizumab + chemotherapy, dostarlimab + chemotherapy [RUBY]) PARPi + IO + chemotherapy (FIRST trial) Considerations associated with chemotherapy vs IO monotherapy, VEGF/IO vs chemotherapy /IO combinations, including safety, PRO (if available)
- |||||||||| Enrollment open: "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 28, 2020
P2, N=600, Recruiting, Brief overview of treatment approaches for MMRp EC patients Current Chemotherapy Future IO monotherapy (dostarlimab, pembrolizumab, avelumab) AI + CDKi (letrozole + palbociclib, NGOT-EN3/NSGO-PALEO study) VEGF + IO (lenvatinib + pembrolizumab, cabozantinib + nivolumab) Chemotherapy + IO (phase 3 trials in progress: pembrolizumab + chemotherapy, atezolizumab + chemotherapy, dostarlimab + chemotherapy [RUBY]) PARPi + IO + chemotherapy (FIRST trial) Considerations associated with chemotherapy vs IO monotherapy, VEGF/IO vs chemotherapy /IO combinations, including safety, PRO (if available) Not yet recruiting --> Recruiting
|